Antiretroviral Agents and Prevention of Malaria in HIV-Infected Ugandan Children
Authors:
- Jane AchanJAJane Achan
- Abel KakuruAKAbel Kakuru
- Gloria IkileziGIGloria Ikilezi
- Theodore RuelTRTheodore Ruel
- Tamara D. ClarkTCTamara D. Clark
- Christian NsanzabanaCNChristian Nsanzabana
- Edwin CharleboisECEdwin Charlebois
- Francesca AweekaFAFrancesca Aweeka
- Grant DorseyGDGrant Dorsey
- Philip J. RosenthalPRPhilip J. Rosenthal
- Diane HavlirDHDiane Havlir
- Moses R. KamyaMKMoses R. Kamya
- 29 November 2012
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 367 (22) , 2110-2118
Abstract
Human immunodeficiency virus (HIV) protease inhibitors show activity against Plasmodium falciparum in vitro. We hypothesized that the incidence of malaria in HIV-infected children would be lower among children receiving lopinavir–ritonavir–based antiretroviral therapy (ART) than among those receiving nonnucleoside reverse-transcriptase inhibitor (NNRTI)–based ART. We conducted an open-label trial in which HIV-infected children 2 months to 5 years of age who were eligible for ART or were currently receiving NNRTI-based ART were randomly assigned to either lopinavir–ritonavir–based ART or NNRTI-based ART and were followed for 6 months to 2 years. Cases of uncomplicated malaria were treated with artemether–lumefantrine. The primary end point was the incidence of malaria. We enrolled 176 children, of whom 170 received the study regimen: 86 received NNRTI-based ART, and 84 lopinavir–ritonavir–based ART. The incidence of malaria was lower among children receiving the lopinavir–ritonavir–based regimen than among those receiving the NNRTI-based regimen (1.32 vs. 2.25 episodes per person-year; incidence-rate ratio, 0.59; 95% confidence interval [CI], 0.36 to 0.97; P=0.04), as was the risk of a recurrence of malaria after treatment with artemether–lumefantrine (28.1% vs. 54.2%; hazard ratio, 0.41; 95% CI, 0.22 to 0.76; P=0.004). The median lumefantrine level on day 7 after treatment for malaria was significantly higher in the lopinavir–ritonavir group than in the NNRTI group. In the lopinavir–ritonavir group, lumefantrine levels exceeding 300 ng per milliliter on day 7 were associated with a reduction of more than 85% in the 63-day risk of recurrent malaria. A greater number of serious adverse events occurred in the lopinavir–ritonavir group than in the NNRTI group (5.6% vs. 2.3%, P=0.16). Pruritus occurred significantly more frequently in the lopinavir–ritonavir group, and elevated alanine aminotransferase levels significantly more frequently in the NNRTI group. Lopinavir–ritonavir–based ART as compared with NNRTI-based ART reduced the incidence of malaria by 41%, with the lower incidence attributable largely to a significant reduction in the recurrence of malaria after treatment with artemether–lumefantrine. Lopinavir–ritonavir–based ART was accompanied by an increase in serious adverse events. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development; ClinicalTrials.gov number, NCT00978068.)Keywords
This publication has 20 references indexed in Scilit:
- In Vitro Sensitivities of Plasmodium falciparum to Different Antimalarial Drugs in UgandaAntimicrobial Agents and Chemotherapy, 2010
- Pharmacokinetics of Artemether-Lumefantrine and Artesunate-Amodiaquine in Children in Kampala, UgandaAntimicrobial Agents and Chemotherapy, 2010
- Lopinavir/Ritonavir Affects Pharmacokinetic Exposure of Artemether/Lumefantrine in HIV-Uninfected Healthy VolunteersJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Stronger Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against Clinical Isolates of Plasmodium vivax than against Those of P. falciparumAntimicrobial Agents and Chemotherapy, 2008
- Effects of trimethoprim-sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan childrenAIDS, 2007
- Combination Therapy for Uncomplicated Falciparum Malaria in Ugandan ChildrenJAMA, 2007
- Antimalarial activity of sera from subjects taking HIV protease inhibitorsAIDS, 2007
- Pharmacokinetic study of artemether–lumefantrine given once daily for the treatment of uncomplicated multidrug‐resistant falciparum malariaTropical Medicine & International Health, 2007
- Selection of Plasmodium falciparum pfmdr1 Alleles following Therapy with Artemether-Lumefantrine in an Area of Uganda where Malaria Is Highly EndemicAntimicrobial Agents and Chemotherapy, 2006
- Potencies of Human Immunodeficiency Virus Protease Inhibitors In Vitro againstPlasmodium falciparumand In Vivo against Murine MalariaAntimicrobial Agents and Chemotherapy, 2006